The crown disease prevention drugs of international pharmaceutical companies, Astraikon, will realize localized production in Wuxi, Jiangsu, China.
According to Xinhua News Agency, Astraikang and Wuxi Yaoming creatures signed a contract at the 2022 Taihu Bay Life and Health Future Conference on Thursday (August 4) to prevent the neutralized antibody combination drug grace on crown disease prevention.The appropriate localized production has achieved strategic cooperation.
According to Astraikon, this crown disease prevention and antibody combination drugs were authorized in the United States at the end of last year.It was approved by the Hong Kong Department of Health in May.
This drug also passed the special import approval of the Lecheng Pioneer District in June this June, which was used for pre -exposure of coronal virus.The drug has been approved and supplied in many countries and regions around the world.
